Evidence map›Paper›PMID 42360503›Full record

ArticleJournal of neurology2026

Plasma p-tau217 best captures early longitudinal cognitive changes in subjective cognitive decline compared with p-tau181 and NfL.

Giulia Giacomucci, Alice Pieri, Silvia Bagnoli, Katia Maria Giametta, Sonia Padiglioni, Valentina Moschini, Carmen Morinelli, Silvia Maria Rita Tabbì, Chiara Sensi, Lorenzo Mistretta and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Giulia GiacomucciDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Viale Pieraccini 6, 50134, Florence, Italy.
Alice PieriDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Viale Pieraccini 6, 50134, Florence, Italy.
Silvia BagnoliDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Viale Pieraccini 6, 50134, Florence, Italy.
Katia Maria GiamettaDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Viale Pieraccini 6, 50134, Florence, Italy.
Sonia PadiglioniRegional Referral Centre for Relational Criticalities - Tuscany Region, Florence, Italy.
Valentina MoschiniDipartimento Neuroscienze E Degli Organi Di Senso, Neurology Unit, Careggi University Hospital, Florence, Italy.
Carmen MorinelliDipartimento Neuroscienze E Degli Organi Di Senso, Neurology Unit, Careggi University Hospital, Florence, Italy.
Silvia Maria Rita TabbìDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Viale Pieraccini 6, 50134, Florence, Italy.
Chiara SensiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Viale Pieraccini 6, 50134, Florence, Italy.
Lorenzo MistrettaDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Viale Pieraccini 6, 50134, Florence, Italy.
Chiara CrucittiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Viale Pieraccini 6, 50134, Florence, Italy.
Benedetta NacmiasDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Viale Pieraccini 6, 50134, Florence, Italy. benedetta.nacmias@unifi.it.ORCID http://orcid.org/0000-0001-9338-9040
Valentina BessiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Viale Pieraccini 6, 50134, Florence, Italy.

Funding

Regione Toscana 20RSVB-PREVIEWRegione Toscana D75F25000050001
6 · The paper itself

Abstract

backgroundBlood-based biomarkers are increasingly used to support the biological diagnosis of Alzheimer's disease (AD), but their prognostic value in subjective cognitive decline (SCD) remains incompletely understood. We investigated whether plasma p-tau217, p-tau181, and neurofilament light chain (NfL) are associated with domain-specific longitudinal cognitive changes in SCD.

methods76 SCD patients underwent plasma biomarker assessment and extensive neuropsychological evaluation at baseline and after two years. Participants were classified according to plasma biomarker status: p-tau217-negative, gray-zone, or positive; p-tau181-negative or positive; and NfL-negative or positive. Linear mixed effects models with random intercepts were used to assess the effects of time, biomarker status, and their interaction on cognitive outcomes.

resultsPlasma p-tau217 showed the most consistent association with longitudinal cognitive trajectories. p-Tau217-positive participants declined in short story delayed recall and visual search, while gray-zone participants showed an intermediate memory trajectory. For category fluency, p-tau217-negative participants improved over time. Plasma p-tau181 showed weaker and less consistent associations, mainly involving memory measures and emerging primarily in post hoc analysis. NfL was associated with a more heterogeneous profile, without a clear pattern of longitudinal cognitive decline. DISCUSSION: Plasma p-tau217 was associated with early domain-specific cognitive vulnerability in SCD, involving episodic memory and attentional functioning. These findings suggest that plasma p-tau217 showed more consistent associations with early domain-specific cognitive changes than p-tau181 and NfL, supporting its role in cognitive stratification of individuals within the earliest stages of the AD continuum.

Indexed as

Cognitive DysfunctionNeurofilament Proteinstau ProteinsAgedBiomarkersDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsBiomarkersMAPT protein, humanneurofilament protein LNeurofilament Proteinstau ProteinsAlzheimer's DiseaseNfLPlasma p-tau181Plasma p-tau217Subjective Cognitive Decline

Identifiers

PMID42360503
PMCPMC13309395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.